janus kinase (JAK) inhibitor for COVID-19 - living meta-analysis of clinical studies

meta|evidence COVID-19

Living systematic review and meta-analysis

vs. potential COVID-19 treatments
vs. control
vs. placebo
vs. standard of care
vs. Vitamins
vs. vitamin C

All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
root
secondary prevention

Studies
Mapping
Meta-analysis
Excluded 1

table network network 2

display ongoing demontrated benefit only

popup

Cantini, 2020

baricitinib vs. standard of care

COVID-19 mild to moderate

Cantini, 2020

baricitinib vs. standard of care

COVID-19 mild to moderate

Rodriguez-Garcia, 2020 EUPAS34966

baricitinib vs. standard of care

COVID-19 mild to moderate

Vergis, 2021 NCT04581954

ruxolitinib vs. standard of care

COVID-19 mild to moderate

Murugesan, 2022

tofacitinib vs. standard of care

COVID-19 mild to moderate

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open